We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
+8.81%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$211M
AUM Growth
+$5.25M
Cap. Flow
+$270M
Cap. Flow %
128.04%
Top 10 Hldgs %
62.31%
Holding
46
New
12
Increased
7
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$13.9M
2
RZLT icon
Rezolute
RZLT
+$6.47M
3
DCTH icon
Delcath Systems
DCTH
+$5.58M
4
CGON icon
CG Oncology
CGON
+$4.65M
5
MYO icon
Myomo
MYO
+$3.23M

Top Sells

Rank Stock Value
1
ABEO icon
Abeona Therapeutics
ABEO
+$8.6M
2
NUVB icon
Nuvation Bio
NUVB
+$4.31M
3
URGN icon
UroGen Pharma
URGN
+$3.91M
4
VSTM icon
Verastem
VSTM
+$3.76M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$3.62M

Sector Composition

Rank Sector Weight
1 Healthcare 97.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMPS
26
Compass Pathways
CMPS
$1.67B
$1.35M 0.64%
482,651
-340,635
-41% -$1.28M
TLPH icon
27
Talphera
TLPH
$68.5M
$922K 0.44%
2,003,939
– –
BFRI icon
28
Biofrontera
BFRI
$14M
$695K 0.33%
976,448
+332,055
+52% +$232K
URGN icon
29
CALL
UroGen Pharma
URGN
$1.96B
$600K 0.28%
+100,000
New +$960K
KURA icon
30
Kura Oncology
KURA
$964M
$577K 0.27%
100,000
– –
XNTK icon
31
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.05B
$534K 0.25%
+550,000
New +$114M
REPL icon
32
CALL
Replimune Group
REPL
$859M
$516K 0.24%
+231,800
New +$2.02M
SPY icon
33
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$433K 0.21%
+250,000
New +$143M
ATYR
34
PUT
aTyr Pharma
ATYR
$50M
$271K 0.13%
+223,000
New +$877K
OVID icon
35
Ovid Therapeutics
OVID
$455M
$165K 0.08%
+500,000
New +$151K
IDYA icon
36
CALL
IDEAYA Biosciences
IDYA
$3.47B
$68K 0.03%
+20,000
New +$384K
CRNX icon
37
CALL
Crinetics Pharmaceuticals
CRNX
$8.88B
$58K 0.03%
+52,700
New +$1.63M
ABEO icon
38
Abeona Therapeutics
ABEO
$399M
– –
-1,805,817
Closed -$8.6M
CADL icon
39
PUT
Candel Therapeutics
CADL
$746M
– –
-15,800
Closed -$3.57K
COGT icon
40
Cogent Biosciences
COGT
$6.68B
– –
-248,285
Closed -$1.49M
KPRX icon
41
Kiora Pharmaceuticals
KPRX
$11.7M
– –
-250,059
Closed -$753K
LXRX icon
42
CALL
Lexicon Pharmaceuticals
LXRX
$1.06B
– –
-1,278,900
Closed -$30K
NUVB icon
43
Nuvation Bio
NUVB
$2.02B
– –
-2,451,500
Closed -$4.31M
OPTN
44
DELISTED
OptiNose
OPTN
– –
-256,190
Closed -$2.35M
QQQ icon
45
PUT
Invesco QQQ Trust
QQQ
$466B
– –
-50,000
Closed -$374K
ACOG
46
Alpha Cognition
ACOG
$185M
– –
-104,836
Closed -$530K
1
2

Similar funds

FGG
Financial Guidance Group Palm Harbor, Florida $249M AUM 17.15% 1-Year Est. Return
TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
TWM
Tumwater Wealth Management Boise, Idaho $249M AUM 21.95% 1-Year Est. Return
DFG
Dupree Financial Group Lexington, Kentucky $248M AUM 26.52% 1-Year Est. Return
FIG
FSA Investment Group Pensacola, Florida $248M AUM 17% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return

Rosalind Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Rosalind Advisors held 46 positions worth $211M, up 2.6% from $206M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Rosalind Advisors deployed $270M of net new capital in Q2 2025, opening 12 new positions and adding to 7 existing holdings. Its largest new stake was Cytokinetics: 400,000 shares worth $13.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was UroGen Pharma, an estimated $3.91M trimmed.

  • Rosalind Advisors's largest Q2 2025 buy was Cytokinetics: 400,000 shares worth $13.2M.
  • Rosalind Advisors added most to Delcath Systems in Q2 2025, an estimated $5.58M increase.
  • Rosalind Advisors's biggest Q2 2025 reduction was UroGen Pharma, cutting an estimated $3.91M.
  • Rosalind Advisors fully exited Abeona Therapeutics in Q2 2025, selling an estimated $8.6M.
  • Rosalind Advisors's ten largest holdings make up 62% of its $211M portfolio in Q2 2025.
  • Rosalind Advisors opened 12 new positions and closed 9 in Q2 2025.
  • Rosalind Advisors's portfolio value rose 2.6% quarter-over-quarter to $211M.

Based on Rosalind Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.